Olga LenÄovÃ¡

List of Publications by Year
in descending order

35	1,735	393982 19	395343 33
papers	citations	h-index	g-index

36	36	36	2483
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacological Reports, 2009, 61, 154-171.	1.5	633
2	Oxidative Stress, Redox Signaling, and Metal Chelation in Anthracycline Cardiotoxicity and Pharmacological Cardioprotection. Antioxidants and Redox Signaling, 2013, 18, 899-929.	2.5	267
3	Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert Opinion on Drug Safety, 2005, 4, 457-472.	1.0	64
4	Comparison of Clinically Used and Experimental Iron Chelators for Protection against Oxidative Stress-Induced Cellular Injury. Chemical Research in Toxicology, 2010, 23, 1105-1114.	1.7	61
5	Proteomic insights into chronic anthracycline cardiotoxicity. Journal of Molecular and Cellular Cardiology, 2011, 50, 849-862.	0.9	57
6	In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity. Toxicology, 2007, 237, 218-228.	2.0	55
7	Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death. British Journal of Cancer, 2009, 101, 792-802.	2.9	53
8	Chronic Anthracycline Cardiotoxicity: Molecular and Functional Analysis with Focus on Nuclear Factor Erythroid 2-Related Factor 2 and Mitochondrial Biogenesis Pathways. Journal of Pharmacology and Experimental Therapeutics, 2012, 343, 468-478.	1.3	48
9	Deferiprone Does Not Protect against Chronic Anthracycline Cardiotoxicity in Vivo. Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 259-269.	1.3	43
10	Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone. British Journal of Pharmacology, 2008, 155, 138-148.	2.7	42
11	Cardioprotective Effects of a Novel Iron Chelator, Pyridoxal 2-Chlorobenzoyl Hydrazone, in the Rabbit Model of Daunorubicin-Induced Cardiotoxicity. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 1336-1347.	1.3	40
12	Molecular Remodeling of Left and Right Ventricular Myocardium in Chronic Anthracycline Cardiotoxicity and Post-Treatment Follow Up. PLoS ONE, 2014, 9, e96055.	1.1	38
13	Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: A study of salicylaldehyde isonicotinoyl hydrazone (SIH). Toxicology, 2007, 235, 150-166.	2.0	32
14	New iron chelators in anthracycline-induced cardiotoxicity. Cardiovascular Toxicology, 2007, 7, 145-150.	1.1	30
15	Myocardial regulatory proteins and heart failure. European Journal of Heart Failure, 2006, 8, 333-342.	2.9	29
16	Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits. Toxicology, 2013, 311, 191-204.	2.0	28
17	In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxicity. Archives of Toxicology, 2011, 85, 525-535.	1.9	24
18	Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation. Circulation: Heart Failure, 2021, 14, e008209.	1.6	24

#	Article	IF	Citations
19	Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo. Toxicology Research, 2015, 4, 1098-1114.	0.9	20
20	Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane. Journal of Molecular and Cellular Cardiology, 2016, 91, 92-103.	0.9	20
21	Protective effects of dexrazoxane against acute ischaemia/reperfusion injury of rat hearts. Canadian Journal of Physiology and Pharmacology, 2012, 90, 1303-1310.	0.7	16
22	Pharmacokinetics of the Cardioprotective Drug Dexrazoxane and Its Active Metabolite ADR-925 with Focus on Cardiomyocytes and the Heart. Journal of Pharmacology and Experimental Therapeutics, 2018, 364, 433-446.	1.3	15
23	HPLC determination of a novel aroylhydrazone iron chelator (o-108) in rabbit plasma and its application to a pilot pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 838, 107-112.	1.2	14
24	Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II<i>Î²</i>Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity. Journal of Pharmacology and Experimental Therapeutics, 2020, 373, 402-415.	1.3	14
25	Proteomic investigation of embryonic rat heart-derived H9c2 cell line sheds new light on the molecular phenotype of the popular cell model. Experimental Cell Research, 2015, 339, 174-186.	1.2	13
26	Safety and tolerability of repeated administration of pyridoxal 2-chlorobenzoyl hydrazone in rabbits. Human and Experimental Toxicology, 2005, 24, 581-589.	1.1	12
27	<i>In vitro</i> and <i>in vivo</i> investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline. Clinical Science, 2019, 133, 1827-1844.	1.8	10
28	Experimental determination of diagnostic window of cardiac troponins in the development of chronic anthracycline cardiotoxicity and estimation of its predictive value. International Journal of Cardiology, 2015, 201, 358-367.	0.8	9
29	Pyridoxal Isonicotinoyl Hydrazone (PIH) and its Analogs as Protectants Against Anthracycline-Induced Cardiotoxicity. Hemoglobin, 2008, 32, 207-215.	0.4	8
30	Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model<i>in vivo</i>. Clinical Science, 2021, 135, 1897-1914.	1.8	8
31	Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIÎ² inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity. Scientific Reports, 2021, 11, 4456.	1.6	6
32	Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?. Toxicology, 2016, 372, 52-63.	2.0	1
33	Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up. Clinical Science, 2022, 136, 139-161.	1.8	1
34	ANTHRACYCLINE CARDIOTOXICITY: THE PHARMACOKINETICS AND PHARMACODYNAMICS OF DEXRAZOXANE AND ITS OPEN RING METABOLITE. Heart, 2014, 100, A7.1-A7.	1.2	0
35	79â€…Effective cardioprotection against anthracycline cardiotoxicity in isolated cardiomyocytes and rabbits is based on dexrazoxane interaction with topoisomerase II beta instead of iron chelation by its metabolite ADR-925. , 2019, , .		0